 | Up a level |
Gluz, Oleg, Scheffen, Iris, Degenhardt, Tom, Marschner, Norbert Walter, Christgen, Matthias, Kreipe, Hans Heinrich, Nitz, Ulrike, Kates, Ronald E., Schinkoethe, Timo, Graeser, Monika Karla, Wuerstlein, Rachel, Kuemmel, Sherko 
ORCID: 0000-0001-9355-494X, Bauer, Lelia, Schem, Christian, Fehm, Tanja N., Neubauer, Hans and Harbeck, Nadia
(2021).
ADAPTlate: A randomized, controlled, open-label, phase III trial on adjuvant dynamic marker-Adjusted personalized therapy comparing abemaciclib combined with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy in (clinical or genomic) high-risk, HR+/HER2-early breast cancer.
J. Clin. Oncol., 39 (15).
PHILADELPHIA:
LIPPINCOTT WILLIAMS & WILKINS.
ISSN 1527-7755
Wirtz, Ralph M., Scheffen, Iris, Marme, Frederik, Laible, Mark, Schlombs, Kornelia, Hake, Roland, Schumacher, Claudia, Schneeweiss, Andreas, Eidt, Sebastian and Sinn, Hans-Peter ORCID: 0000-0003-2836-6699
(2016).
Predictive value of ultra-high ESR1 mRNA expression in early breast cancer.
J. Clin. Oncol., 34 (15).
ALEXANDRIA:
AMER SOC CLINICAL ONCOLOGY.
ISSN 1527-7755